Presented here is the clinical course of a 63-yearold patient with a central, large and unresectable hepatocellular carcinoma(HCC) with liver metastases and tumor invasion of the portal and hepatic veins. After the tu...Presented here is the clinical course of a 63-yearold patient with a central, large and unresectable hepatocellular carcinoma(HCC) with liver metastases and tumor invasion of the portal and hepatic veins. After the tumor had been diagnosed, the patient was immediately treated with proton beam therapy(PBT), at a total dose of 60 Gy(relative biological effectiveness) in 20 fractions administered within 4 wk. To manage the respiratory movements, at the Rinecker Proton Therapy Center, apneic oxygenation was given daily, under general anesthesia. The patient tolerated both the PBT and general anesthesia very well, and did now show any signs of acute or late toxicity. The treatment was followed by constant reductions in the tumor marker alpha-fetoprotein and the cholestatic parameters gamma-glutamyltransferase and alkaline phosphatase. The patient commenced an adjuvant treatment with sorafenib, given at 6-wk intervals, after the PBT. Follow-up with regular magnetic resonance imaging has continued for 40 mo so far, demonstrating remarkable shrinkage of the HCC(maximal diameter dropping from approximately 13 cm to 2 cm). To date, the patient remains free of tumor recurrence. PBT served as a safe and effective treatment method for an unresectable HCC with vascular invasion.展开更多
【目的】评价经鼻高流量吸氧在全麻诱导前行预充氧的有效性及在插管期延长"安全窒息时限"的效果。【方法】随机将80例非困难气道病例纳入全麻面罩组(FM)、全麻面罩复合经鼻高流量吸氧组(FM+HFNCI)、经鼻高流量吸氧组(HFNCI)...【目的】评价经鼻高流量吸氧在全麻诱导前行预充氧的有效性及在插管期延长"安全窒息时限"的效果。【方法】随机将80例非困难气道病例纳入全麻面罩组(FM)、全麻面罩复合经鼻高流量吸氧组(FM+HFNCI)、经鼻高流量吸氧组(HFNCI)以及经鼻高流量吸氧复合鼻咽通气道组(HFNCI+NPA)。麻醉诱导前预充氧阶段,FM及FM+HFNCI组经全麻面罩而HFNCI及HFNCI+NPA组经鼻导管行预充氧;在气管插管期,除FM组外,余患者均接受经鼻高流量氧吹入。记录不同时点血氧分压、血氧饱和度、心率及血压。【结果】预充氧结束时,PaO_2值、SaO_2值在各组间差异无统计学意义(P>0.05)。窒息插管期,PaO_2值在FM组下降明显,而在HFNCI+NPA组上升;FM组ΔPaO_2值最大(均数为-5.4 k Pa),与其余组比较(ΔPaO_2值均数在FM+HFNCI、HFNCI及HFNCI+NPA组分别为-0.5、-0.8、1.4 k Pa)差异有统计学意义(P<0.001)。插管成功时FM、FM+HFNCI、HFNCI、HFNCI+NPA组PaO_2值(均数分别为46.7、48.3、37.7、43.7 k Pa)、SaO_2值(均数分别为99.7%、99.8%、99.4%、99.7%)均远高于各自安全低限值。【结论】HFNCI用于非困难气道病例,麻醉诱导前预充氧有效性高、可能延长"安全窒息时限",提高围插管期安全;为达最佳氧合效果,实施HFNCI时应保证气道通畅。展开更多
目的评价经鼻咽导管窒息氧合技术对重度阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者全麻诱导气管插管时无通气安全时间的影响。方法择期行全麻腭咽成形术的重度OSAHS患者80例,男62例,女18例,年龄18~56岁,BMI 30~42 kg/m^2,ASAⅠ或Ⅱ级,...目的评价经鼻咽导管窒息氧合技术对重度阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者全麻诱导气管插管时无通气安全时间的影响。方法择期行全麻腭咽成形术的重度OSAHS患者80例,男62例,女18例,年龄18~56岁,BMI 30~42 kg/m^2,ASAⅠ或Ⅱ级,改良Mallampati分级Ⅰ-Ⅲ级。采用随机数字法分为两组:经鼻咽导管窒息氧合组(N组)和对照组(C组),每组40例。两组均采用相同的全凭静脉诱导方案,诱导后模拟长时间气管插管。N组意识消失后置入鼻咽导管,确认可以面罩通气,给予肌松药待肌松效果满意后置入喉镜暴露声门结构,并在此时开始经鼻咽导管给予15 L/min湿化纯氧。C组常规麻醉诱导,肌松效果满意后置入喉镜暴露声门结构。记录两组停止面罩通气时的呼气末氧浓度(C ET O 2)、面罩通气停止后SpO 2达到的最低值、插管后开始通气时的P ET CO 2。记录患者无通气安全时间(停止面罩通气至患者SpO 2降至95%的时间),插管后开始通气至SpO 2恢复至100%时间。记录术后24 h鼻腔出血、牙齿损伤、咽喉痛、声音嘶哑、口咽出血等气管插管相关并发症的发生情况。结果与C组比较,N组面罩通气停止后SpO 2达到的最低值明显升高(P<0.05),插管后开始通气时的P ET CO 2明显升高(P<0.05),无通气安全时间明显延长(P<0.05),插管后开始通气至SpO 2回复至100%的时间明显缩短(P<0.05)。两组面罩通气停止时的C ET O 2差异无统计学意义。两组鼻腔出血、牙齿损伤、咽喉痛、声音嘶哑、口咽出血等气管插管相关并发症差异无统计学意义。结论经鼻咽导管窒息氧合技术安全、简便,可以延长重度OSAHS患者全麻诱导气管插管时无通气安全时间,提高其全麻诱导的安全性。展开更多
基金Supported by Rinecker Proton Therapy Center(RPTC),Munich,Germany
文摘Presented here is the clinical course of a 63-yearold patient with a central, large and unresectable hepatocellular carcinoma(HCC) with liver metastases and tumor invasion of the portal and hepatic veins. After the tumor had been diagnosed, the patient was immediately treated with proton beam therapy(PBT), at a total dose of 60 Gy(relative biological effectiveness) in 20 fractions administered within 4 wk. To manage the respiratory movements, at the Rinecker Proton Therapy Center, apneic oxygenation was given daily, under general anesthesia. The patient tolerated both the PBT and general anesthesia very well, and did now show any signs of acute or late toxicity. The treatment was followed by constant reductions in the tumor marker alpha-fetoprotein and the cholestatic parameters gamma-glutamyltransferase and alkaline phosphatase. The patient commenced an adjuvant treatment with sorafenib, given at 6-wk intervals, after the PBT. Follow-up with regular magnetic resonance imaging has continued for 40 mo so far, demonstrating remarkable shrinkage of the HCC(maximal diameter dropping from approximately 13 cm to 2 cm). To date, the patient remains free of tumor recurrence. PBT served as a safe and effective treatment method for an unresectable HCC with vascular invasion.
文摘【目的】评价经鼻高流量吸氧在全麻诱导前行预充氧的有效性及在插管期延长"安全窒息时限"的效果。【方法】随机将80例非困难气道病例纳入全麻面罩组(FM)、全麻面罩复合经鼻高流量吸氧组(FM+HFNCI)、经鼻高流量吸氧组(HFNCI)以及经鼻高流量吸氧复合鼻咽通气道组(HFNCI+NPA)。麻醉诱导前预充氧阶段,FM及FM+HFNCI组经全麻面罩而HFNCI及HFNCI+NPA组经鼻导管行预充氧;在气管插管期,除FM组外,余患者均接受经鼻高流量氧吹入。记录不同时点血氧分压、血氧饱和度、心率及血压。【结果】预充氧结束时,PaO_2值、SaO_2值在各组间差异无统计学意义(P>0.05)。窒息插管期,PaO_2值在FM组下降明显,而在HFNCI+NPA组上升;FM组ΔPaO_2值最大(均数为-5.4 k Pa),与其余组比较(ΔPaO_2值均数在FM+HFNCI、HFNCI及HFNCI+NPA组分别为-0.5、-0.8、1.4 k Pa)差异有统计学意义(P<0.001)。插管成功时FM、FM+HFNCI、HFNCI、HFNCI+NPA组PaO_2值(均数分别为46.7、48.3、37.7、43.7 k Pa)、SaO_2值(均数分别为99.7%、99.8%、99.4%、99.7%)均远高于各自安全低限值。【结论】HFNCI用于非困难气道病例,麻醉诱导前预充氧有效性高、可能延长"安全窒息时限",提高围插管期安全;为达最佳氧合效果,实施HFNCI时应保证气道通畅。
文摘目的评价经鼻咽导管窒息氧合技术对重度阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者全麻诱导气管插管时无通气安全时间的影响。方法择期行全麻腭咽成形术的重度OSAHS患者80例,男62例,女18例,年龄18~56岁,BMI 30~42 kg/m^2,ASAⅠ或Ⅱ级,改良Mallampati分级Ⅰ-Ⅲ级。采用随机数字法分为两组:经鼻咽导管窒息氧合组(N组)和对照组(C组),每组40例。两组均采用相同的全凭静脉诱导方案,诱导后模拟长时间气管插管。N组意识消失后置入鼻咽导管,确认可以面罩通气,给予肌松药待肌松效果满意后置入喉镜暴露声门结构,并在此时开始经鼻咽导管给予15 L/min湿化纯氧。C组常规麻醉诱导,肌松效果满意后置入喉镜暴露声门结构。记录两组停止面罩通气时的呼气末氧浓度(C ET O 2)、面罩通气停止后SpO 2达到的最低值、插管后开始通气时的P ET CO 2。记录患者无通气安全时间(停止面罩通气至患者SpO 2降至95%的时间),插管后开始通气至SpO 2恢复至100%时间。记录术后24 h鼻腔出血、牙齿损伤、咽喉痛、声音嘶哑、口咽出血等气管插管相关并发症的发生情况。结果与C组比较,N组面罩通气停止后SpO 2达到的最低值明显升高(P<0.05),插管后开始通气时的P ET CO 2明显升高(P<0.05),无通气安全时间明显延长(P<0.05),插管后开始通气至SpO 2回复至100%的时间明显缩短(P<0.05)。两组面罩通气停止时的C ET O 2差异无统计学意义。两组鼻腔出血、牙齿损伤、咽喉痛、声音嘶哑、口咽出血等气管插管相关并发症差异无统计学意义。结论经鼻咽导管窒息氧合技术安全、简便,可以延长重度OSAHS患者全麻诱导气管插管时无通气安全时间,提高其全麻诱导的安全性。
